Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool April 11, 2011 Jim Mueller	A Missed Opportunity Cephalon showed up on my screen as a potential buy, but others liked it, too.
The Motley Fool December 31, 2010 Brian Orelli	How the Other Half of Pharma Lives A dive into spec pharma.
The Motley Fool May 3, 2011 Brian Orelli	Teva's Branded-Drug Binge For a company that's a generic-drug maker, Teva Pharmaceuticals sure does like its branded drugs. Despite the warts the company is ponying up $6.2 billion to buy Cephalon.
The Motley Fool February 14, 2008 Brian Lawler	Waking Cephalon Up Specialty pharma Cephalon presents its 2007 financial results and 2008 guidance.
The Motley Fool September 30, 2008 Brian Orelli	Pharma, Cash, and You Pharma's been saving for a rainy day, and there's a thunderstorm outside.
The Motley Fool November 9, 2007 Brian Lawler	Cephalon Wheels and Deals Sales and net income fall in the third quarter, but increased guidance sends shares of the drugmaker higher.
BusinessWeek June 16, 2011 Mider & McCracken	M&A: The Markets Love a Buyer Contrary to conventional wisdom, the announcement of an acquisition is likely to lift the stock price of the company doing the buying.
The Motley Fool April 1, 2008 Brian Lawler	Cephalon Plays "Let's Make a Deal" Cephalon acquires an oncology drug on the cheap from tiny Acusphere.
The Motley Fool February 16, 2007 Brian Lawler	Cephalon's Supercharged Growth The pharmaceutical announces fourth-quarter results and updates 2007 guidance. Investors, take note.
The Motley Fool April 27, 2007 Brian Lawler	Cephalon's Earnings Surprise The drugmaker raises its earnings guidance for the year. With no serious competition for its lead compounds in the near term, investors should take a look at the well-run pharma.
The Motley Fool March 12, 2009 Robert Steyer	A Valeant Effort During this decade, Valeant has had four CEOs, two names, and multiple strategies. And now the constantly changing drugmaker is trying another.
The Motley Fool August 27, 2007 Brian Lawler	Cephalon Makes A Deal The newest drug in its cabinet is expected to hit the U.S. market in the fourth quarter. Investors will know relatively soon whether Cephalon pulled off another coup or just flushed $100 million down the toilet.
Chemistry World May 4, 2011 Andrew Turley	Teva sidelines Valeant with $6.8bn Cephalon bid US drugmaker Cephalon has agreed to a $6.8 billion ( 4.1 billion) takeover bid from Israeli generics manufacturer Teva, which has beaten into second place Canadian pharma company Valeant.
Chemistry World March 25, 2015 Phillip Broadwith	Valeant heads off Endo bid for Salix Valeant has flexed its acquisitive muscles to head off a rival bid for gastroenterology specialist Salix Pharmaceuticals.
Chemistry World May 26, 2015 Phillip Broadwith	Endo to buy Par as generics consolidation continues Irish-headquartered firm Endo Pharmaceuticals has agreed to buy private US firm Par Pharmaceuticals in a deal worth around $8 billion in a combination of cash, shares and assumed debt.
The Motley Fool December 2, 2010 Brian Orelli	A Short FDA Delay. For What? GlaxoSmithKline and Valeant aren't saying.
The Motley Fool June 2, 2009 Brian Orelli	ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies.
The Motley Fool July 6, 2006 Brian Lawler	Cephalon on the Hunt The biopharma company is looking to make more acquisitions and gets some good news from the FDA. Cephalon's stock climbed by more than 10% after the announcement.
The Motley Fool September 26, 2006 Brian Lawler	A Savior for Cephalon? The FDA's approval of Fentora comes just in time for the drug company. Investors, take note.
The Motley Fool August 24, 2010 Travers & Jayson	Will Valeant Pharmaceuticals Burn You? How well has Valeant Pharmaceuticals International tapped the capital markets? Here's a visual summary of the past few years
The Motley Fool April 2, 2007 Brian Lawler	FDA Keeps Cephalon Waiting The FDA issues Cephalon an approvable letter for one of its drugs. Investors, take note.
The Motley Fool March 30, 2010 Brian Orelli	FDA Lags, Investors Flee Cephalon gets no love from the FDA. The agency failed to expand Cephalon's Nuvigil for the treatment of jet lag.
The Motley Fool August 3, 2007 Brian Lawler	Cephalon's Case of Spending Blues Cephalon announces its second-quarter financial results. Sales were up, so why is the share price down? Perhaps escalating SG&A expenses are the culprit.
Chemistry World July 30, 2013 Emma Stoye	Thousands face job cuts after Valeant's Bausch buyout Canadian pharmaceutical company Valeant plans to lay off up to 2700 staff to help finance its $8.7 billion acquisition of US eye health specialist Bausch & Lomb.
The Motley Fool August 17, 2010 Travers & Jayson	Interested in Cephalon ? Start Here! Every biotech company wants to discover the cure for cancer, Alzheimer's, or Wii knee. Every biotech investor hopes to catch the next Valeant Pharmaceuticals.
The Motley Fool August 19, 2011 Cindy Johnson	12 Pharmaceutical Stocks the Insiders Are Buying Folks in the know think these pharmaceutical stocks will rise. Should you join them?
Chemistry World February 23, 2015 Phillip Broadwith	Valeant to buy Salix for $14.5bn Serial acquirer Valeant has agreed to buy gastroenterology specialist Salix Pharmaceuticals for $14.5 billion
Chemistry World September 10, 2015 Katrina Megget	Merger fever sweeps pharma Cheap financing, among other factors, is allowing companies to stock their drug pipelines through acquisitions
Chemistry World November 24, 2014 Andy Extance	Actavis rescues Allergan with $66 billion deal The acrimonious seven-month battle over the future of US biotech Allergan looks to be over, after the Botox-maker accepted a 'white knight' takeover bid from Actavis.
Pharmaceutical Executive December 1, 2008 Walter Armstrong	The New Deals Everything you wanted to know about the year's most important deals, and what to watch for in the future.
Chemistry World October 21, 2011 Sarah Houlton	Abbott Splits to Set Pharma Portfolio Free Abbott Laboratories is to be split in two and claims the aim is to strengthen the outlook for growth and shareholder returns.
The Motley Fool September 30, 2011 Brian Orelli	When You Need More Than Just a Low-Margin Business Teva Pharmaceuticals, arguably the largest generic-drug maker, can use economies of scale more easily than smaller companies like Watson Pharmaceuticals or Par Pharmaceutical, but it's still pushing further into branded drugs.
The Motley Fool November 4, 2004 Charly Travers	Drug Growth Screeching to a Halt Given the threat of generics to not-so-small drug company Cephalon's product line, the acquisition of CIMA labs in August of this year could turn out to be quite important.
Chemistry World July 28, 2014 Andy Extance	Takeover battle pushes Allergan to cut R&D jobs Despite a quarterly sales increase it describes as its strongest ever, Botox maker Allergan is laying off 1500 staff as it seeks to fend off a hostile takeover.
The Motley Fool September 14, 2007 Brian Lawler	"Dear Doctor" Letter Spells Trouble for Cephalon Cephalon sends a letter to health-care practitioners warning of the dangers of misusing one of its lead drugs, Fentora. Investors, take note.
Chemistry World September 6, 2012 Andrew Turley	Valeant buys $2.6bn skincare firm Canadian pharma company Valeant is to buy US firm Medicis in a $2.6 billion deal. Medicis produces prescription dermatology products as well as over the counter products.
Pharmaceutical Executive November 1, 2005 Sara Calabro	Valeant Pharmaceuticals is Soldiering On Valeant Pharmaceuticals' new CEO Tim Tyson restructures the company after legal and financial troubles.
Pharmaceutical Executive May 1, 2012	Pharm Exec 50: Growth from the Bottom Up More consolidation didn't boost pharmaceutical sales at the top, but a handful of nimble newcomers posted impressive growth on the other end of the curve.
The Motley Fool May 2, 2011 Arundhati Parmar	Teva pays $6.8B to buy Cephalon, including Minnesota's CIMA Labs Teva diversifies.
The Motley Fool April 16, 2008 Brian Lawler	Cephalon Convinces the Continent The pharmaceutical's lead pain drug gets approved for marketing in Europe.
The Motley Fool December 31, 2007 Brian Lawler	Cephalon's Date With the FDA In the last day of the year, Cephalon announces that it has submitted another New Drug Application for oncology treatment Treanda. Expect to hear back from FDA on this priority review before the middle of 2008.
Pharmaceutical Executive December 1, 2013 Peter Young	2013 Pharma and Biotech Financial Report Big Pharma and biotech continue to need each other. But biotech is feeling slightly more confident as the options for IPOs get better.
The Motley Fool August 19, 2004 Charly Travers	1 Pill for Sleep, Attention Ailments? Cephalon gets some good news about its drug PROVIGIL.
The Motley Fool April 12, 2011 Sean Williams	This Deal May Be Doomed From the Start See why Level 3's purchase of Global Crossing might be set up to fail.
The Motley Fool June 27, 2006 Brian Lawler	Cephalon Stays Busy The announcement of Gabitril's phase 3 failure was definitely not good news for Cephalon. However, if the market panics and drives the stock down, investors could find themselves with a great buying opportunity.
The Motley Fool August 13, 2004 Rich Duprey	Cima's Breakup Mess The pharmaceutical company seeks to recoup its fees plus damages from a former suitor.
The Motley Fool January 30, 2006 Stephen D. Simpson	Speed the Plough Schering-Plough is still in a precarious position, but it's likely to have above-average growth. It is also one of the few pharmaceuticals whose risk level is actually decreasing. This could be a stock worth owning for some time.
Pharmaceutical Executive January 1, 2011	The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade.
The Motley Fool June 16, 2011 Brian Orelli	Are Two FDA Approvals in One Week a Positive Sign? Bristol-Myers Squibb received Food and Drug Administration approval for its kidney transplant drug Nulojix yesterday, marking the second approval this week from the FDA.
The Motley Fool February 17, 2006 Brian Gorman	Enthusiasm for Cephalon The company seems to be counting on a strong showing for a new drug, but for investors, it may pay to be cautious.